Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT) - PubMed (original) (raw)
Clinical Trial
. 2018 Aug;79(2):266-276.e5.
doi: 10.1016/j.jaad.2018.04.013. Epub 2018 Apr 14.
Affiliations
- PMID: 29660425
- DOI: 10.1016/j.jaad.2018.04.013
Free article
Clinical Trial
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
Mark Lebwohl et al. J Am Acad Dermatol. 2018 Aug.
Free article
Abstract
Background: Phase 2 psoriasis studies with the Fc-free, PEGylated, anti-tumor necrosis factor biologic certolizumab pegol demonstrated meaningful clinical activity.
Objective: Assess safety and efficacy of certolizumab in adults with moderate-to-severe chronic plaque psoriasis.
Methods: Patients were randomized 3:3:1:3 to certolizumab 400 mg, certolizumab 200 mg, or placebo every 2 weeks for 16 weeks or etanercept 50 mg twice weekly for 12 weeks. Certolizumab-treated patients achieving a ≥75% reduction in Psoriasis Area and Severity Index (PASI) at week 16 from baseline PASI were rerandomized to certolizumab or placebo for 32 weeks. The primary endpoint was responder rate (≥75% reduction in PASI from baseline PASI) versus placebo (primary analysis) and etanercept (secondary analysis) at week 12; secondary endpoints included responder rates on various measures versus placebo at weeks 12, 16, and 48. Safety was assessed by treatment-emergent adverse events.
Results: All endpoints were significantly greater for certolizumab versus placebo with the greatest response seen with 400 mg. Certolizumab 400 mg was superior to and 200 mg was noninferior to etanercept. Adverse events were consistent with the anti-tumor necrosis factor class of drugs.
Limitations: Etanercept was administered by unblinded study staff or self-administered, but efficacy assessments were performed by a blinded assessor.
Conclusion: Both certolizumab regimens improved psoriasis symptoms, with a greater response seen with the higher dose. No new safety signals were observed.
Keywords: CIMPACT; anti-TNF; anti–tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; etanercept; phase 3 trial.
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
- Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K. Gottlieb AB, et al. J Am Acad Dermatol. 2018 Aug;79(2):302-314.e6. doi: 10.1016/j.jaad.2018.04.012. Epub 2018 Apr 13. J Am Acad Dermatol. 2018. PMID: 29660421 Clinical Trial. - Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB. Blauvelt A, et al. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):546-552. doi: 10.1111/jdv.15258. Epub 2018 Oct 14. J Eur Acad Dermatol Venereol. 2019. PMID: 30242918 Free PMC article. - Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis.
Lee A, Scott LJ. Lee A, et al. BioDrugs. 2020 Apr;34(2):235-244. doi: 10.1007/s40259-020-00416-z. BioDrugs. 2020. PMID: 32207094 Review. - Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
Warren RB, Lebwohl M, Sofen H, Piguet V, Augustin M, Brock F, C Arendt, Fierens F, Blauvelt A. Warren RB, et al. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):2398-2408. doi: 10.1111/jdv.17486. Epub 2021 Aug 17. J Eur Acad Dermatol Venereol. 2021. PMID: 34192387 Free PMC article. Clinical Trial. - An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM. Weinberg JM. Clin Ther. 2003 Oct;25(10):2487-505. doi: 10.1016/s0149-2918(03)80313-2. Clin Ther. 2003. PMID: 14667953 Review.
Cited by
- Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases.
Veerasubramanian PK, Wynn TA, Quan J, Karlsson FJ. Veerasubramanian PK, et al. J Exp Med. 2024 Nov 4;221(11):e20240806. doi: 10.1084/jem.20240806. Epub 2024 Sep 19. J Exp Med. 2024. PMID: 39297883 Free PMC article. Review. - IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis.
Aggarwal P, Fleischer AB Jr. Aggarwal P, et al. J Clin Med. 2024 Aug 29;13(17):5139. doi: 10.3390/jcm13175139. J Clin Med. 2024. PMID: 39274352 Free PMC article. - A Systematic Review Evaluating the Effectiveness of Several Biological Therapies for the Treatment of Skin Psoriasis.
Alzahrani SA, Alzamil FM, Aljuhni AM, Al Thaqfan NA, Alqahtani NY, Alwarwari SA, Alkharashi AA, Alzabadin RA, Alzehairi RA, Alhajlah AA. Alzahrani SA, et al. Cureus. 2023 Dec 15;15(12):e50588. doi: 10.7759/cureus.50588. eCollection 2023 Dec. Cureus. 2023. PMID: 38222196 Free PMC article. Review. - A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis.
Coto-Segura P, Segú-Vergés C, Martorell A, Moreno-Ramírez D, Jorba G, Junet V, Guerri F, Daura X, Oliva B, Cara C, Suárez-Magdalena O, Abraham S, Mas JM. Coto-Segura P, et al. Front Immunol. 2023 Sep 20;14:1212981. doi: 10.3389/fimmu.2023.1212981. eCollection 2023. Front Immunol. 2023. PMID: 37809085 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical